Jazz Pharmaceuticals (JAZZ)
NASDAQ:JAZZ
Want to see JAZZ full AI Analyst Report?
Total Valuation
Jazz Pharmaceuticals has a market cap or net worth of $14.35B. The enterprise value is $17.93B.
Market Cap$14.35B
Enterprise Value$17.93B
Share Statistics
Jazz Pharmaceuticals has 62,742,820 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding62,742,820
Owned by Insiders3.59%
Owned by Institutions31.27%
Financial Efficiency
Jazz Pharmaceuticals’s return on equity (ROE) is -0.08 and return on invested capital (ROIC) is 1.22%.
Return on Equity (ROE)-0.08
Return on Assets (ROA)-0.03
Return on Invested Capital (ROIC)1.22%
Return on Capital Employed (ROCE)0.02
Revenue Per Employee1.52M
Profits Per Employee-127.20K
Employee Count2,800
Asset Turnover0.37
Inventory Turnover1.21
Valuation Ratios
The current PE Ratio of Jazz Pharmaceuticals is 10.0. Jazz Pharmaceuticals’s PEG ratio is 0.18.
PE Ratio10.0
PS Ratio2.43
PB Ratio2.40
Price to Fair Value2.40
Price to FCF7.99
Price to Operating Cash Flow10.61
PEG Ratio0.18
Income Statement
In the last 12 months, Jazz Pharmaceuticals had revenue of 4.27B and earned -356.15M in profits. Earnings per share was -5.84.
Revenue4.27B
Gross Profit3.76B
Operating Income224.42M
Pretax Income-628.59M
Net Income-356.15M
EBITDA108.46M
Earnings Per Share (EPS)-5.84
Cash Flow
In the last 12 months, operating cash flow was 1.33B and capital expenditures -88.57M, giving a free cash flow of 1.25B billion.
Operating Cash Flow1.33B
Free Cash Flow1.25B
Free Cash Flow per Share19.85
Dividends & Yields
Jazz Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.73
52-Week Price Change108.39%
50-Day Moving Average183.03
200-Day Moving Average151.89
Relative Strength Index (RSI)67.75
Average Volume (3m)861.05K
Important Dates
Jazz Pharmaceuticals upcoming earnings date is Aug 11, 2026, After Close (Confirmed).
Last Earnings DateMay 5, 2026
Next Earnings DateAug 11, 2026
Ex-Dividend Date―
Financial Position
Jazz Pharmaceuticals as a current ratio of 1.86, with Debt / Equity ratio of 119.52%
Current Ratio1.86
Quick Ratio1.67
Debt to Market Cap0.52
Net Debt to EBITDA37.17
Interest Coverage Ratio1.15
Taxes
In the past 12 months, Jazz Pharmaceuticals has paid -272.44M in taxes.
Income Tax-272.44M
Effective Tax Rate0.43
Enterprise Valuation
Jazz Pharmaceuticals EV to EBITDA ratio is 132.76, with an EV/FCF ratio of 11.10.
EV to Sales3.37
EV to EBITDA132.76
EV to Free Cash Flow11.10
EV to Operating Cash Flow10.62
Balance Sheet
Jazz Pharmaceuticals has $2.87B in cash and marketable securities with $5.42B in debt, giving a net cash position of -$2.54B billion.
Cash & Marketable Securities$2.87B
Total Debt$5.42B
Net Cash-$2.54B
Net Cash Per Share-$40.52
Tangible Book Value Per Share-$31.82
Margins
Gross margin is 84.12%, with operating margin of 5.26%, and net profit margin of -8.35%.
Gross Margin84.12%
Operating Margin5.26%
Pretax Margin-14.73%
Net Profit Margin-8.35%
EBITDA Margin2.54%
EBIT Margin-10.16%
Analyst Forecast
The average price target for Jazz Pharmaceuticals is $241.43, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$241.43
Price Target Upside18.68% Upside
Analyst ConsensusStrong Buy
Analyst Count15
Revenue Growth Forecast9.20%
EPS Growth Forecast-94.01%